Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left guessing how to achieve similar results.

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

eHealth Africa Academy has graduated 92 students across Nigeria and Africa, building their capacities in advanced javascript and data analytics. The organisation said this was part of its goal to ...

Pret Advanced Materials, LLC, a supplier of thermoplastic resins, has announced an expansion of its operations in Florence County, SC. The $18.5M investment will enhance the company's capabilities and ...

Have you ever spent precious minutes, or even hours, searching for a document, only to realize it wasn’t labeled or organized properly? In the fast-paced world of digital work, disorganized files can ...

JavaScript is a sprawling and ever-changing behemoth, and may be the single-most connective piece of web technology. From AI to functional programming, from the client to the server, here are nine ...

WhatsApp has introduced Advanced Chat Privacy, a feature that builds on its end-to-end encryption to keep your messages as private as possible by keeping chats in the ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Alphabet Inc.'s (NASDAQ:GOOG) (NASDAQ:GOOGL) Isomorphic Labs says its first artificial-intelligence-designed medicines are nearly ready for human testing. What Happened: Isomorphic Labs President ...